Multiple-dose Pharmacokinetics Study of Tolvaptan Tablets in Chinese Patients With Hepatocirrhosis

Inclusion Criteria: 1. Hepatic Cirrhosis with ascites or lower extremities edema 2. Hospitalized patients 3. 18 years old\~75 years old 4. Inform Consent Form Signed Exclusion Criteria: 1. Patients with any of the following diseases, complications or symptoms: * Hepatic encephalopathy (coma degree classification note 1 Grade 2 or above); * Malignant ascites; * Spontaneous bacterial peritonitis; * Likely to have gastrointestinal bleeding during the study period; * Heart failure (NYHA Note 2 Class Ⅲ andⅣ); * Anuria (daily urine output below 100mL); * Dysuria induced by urinary tract stenosis, calculus, or tumor. 2. Patients with any of the following history: * With gastrointestinal bleeding within 10 days prior to screening; * With cerebrovascular accident within 1 month prior to screening; * With gout attack within 1 month prior to screening; * With allergy or atopy to benzodiazepine drugs (benazepril hydrochloride, etc.). 3. Patients whose systolic blood pressure is below 90mmHg during screening; 4. Patients with abnormal values in the following lab examination indicators: Serum creatinine higher than 2.5 times the upper limit of normal range, serum Na+\>145mmol/L(or higher than the upper limit of normal range), serum K+\> 5.5 mmol/L, uric acid\>476µmol/L, child-Pugh score\>10 5. Patients ineligible for oral medication 6. Patients in pregnancy or lactation; female of childbearing potential not taking contraceptive measures; 7. Patients having taken blood products including albumin products within 4 days prior to application of investigational product; 8. Patients having participated in clinical trials of other drugs within 1 month prior to screening; 9. Patients used to participate in clinical trials of Tolvaptan and take the said drug; 10. Patients determined by the investigator as illegible for the study.